These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38614269)

  • 1. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis.
    Fujiwara Y; Karol AB; Joshi H; Reford E; Izadmehr S; Doroshow DB; Galsky MD
    Crit Rev Oncol Hematol; 2024 May; 197():104352. PubMed ID: 38614269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis.
    Liu H; Chen J; Huang Y; Zhang Y; Ni Y; Xu N; Zhao F; Tang Y; Liu H; Sun G; Shen P; Liu Z; Huang J; Liao B; Zeng H
    Int J Surg; 2024 Jun; 110(6):3923-3936. PubMed ID: 38573063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive Protein Is a Prognostic Factor for Survival in Metastatic Upper Tract Urothelial Carcinoma Patients Receiving Pembrolizumab.
    Nagasaka H; Yamamoto S; Suzuki A; Usui K; Terao H; Nakaigawa N; Kishida T
    In Vivo; 2024; 38(4):1823-1828. PubMed ID: 38936923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy.
    Obata J; Kikuchi E; Tanaka N; Matsumoto K; Hayakawa N; Ide H; Miyajima A; Nakagawa K; Oya M
    Urol Oncol; 2013 Nov; 31(8):1725-30. PubMed ID: 23141922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
    Fukuokaya W; Akazawa K; Kimura T
    Anticancer Res; 2024 May; 44(5):2117-2123. PubMed ID: 38677745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
    Klümper N; Sikic D; Saal J; Büttner T; Goldschmidt F; Jarczyk J; Becker P; Zeuschner P; Weinke M; Kalogirou C; Breyer J; Burger M; Nuhn P; Tully K; Roghmann F; Bolenz C; Zengerling F; Wirtz RM; Muders M; Kristiansen G; Bald T; Ellinger J; Wullich B; Hölzel M; Hartmann A; Erben P; Ritter M; Eckstein M
    Eur J Cancer; 2022 May; 167():13-22. PubMed ID: 35366569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evaluation of monocyte lymphocyte ratio as a preoperative predictor in urothelial malignancies: a pooled analysis based on comparative studies.
    Zhu X; Wu SQ; Xu R; Wang YH; Zhong ZH; Zhang L; Zhao XK
    Sci Rep; 2019 Apr; 9(1):6280. PubMed ID: 31000754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis.
    Monteiro FSM; Soares A; Mollica V; Leite CA; Carneiro APCD; Rizzo A; Bourlon MT; Sasse AD; Santoni M; Gupta S; Massari F
    Crit Rev Oncol Hematol; 2024 Apr; 196():104321. PubMed ID: 38460929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Routine Laboratory Parameters in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Long-Term Follow-Up.
    Tamalunas A; Buchner A; Kretschmer A; Jokisch F; Schulz G; Eismann L; Stief CG; Grimm T
    Urol Int; 2020; 104(7-8):551-558. PubMed ID: 32114587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Mori K; Mostafaei H; Enikeev DV; Lysenko I; Quhal F; Kimura S; Karakiewicz PI; Egawa S; Shariat SF
    J Urol; 2020 Jul; 204(1):58-62. PubMed ID: 31995432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma.
    Maiorano BA; Schinzari G; Carbone C; Piro G; Rossi E; Di Maio M; Di Giacomo A; Maiello E
    Front Immunol; 2024; 15():1401214. PubMed ID: 38799450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis.
    Dai J; Tang K; Xiao W; Yu G; Zeng J; Li W; Zhang YQ; Xu H; Chen ZQ; Ye ZQ
    Asian Pac J Cancer Prev; 2014; 15(8):3369-75. PubMed ID: 24870724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comment on 'Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis'.
    Zhao J; Xu Q
    Int J Surg; 2024 Sep; 110(9):5895-5896. PubMed ID: 38801467
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis.
    Zhou L; Cai X; Liu Q; Jian ZY; Li H; Wang KJ
    Sci Rep; 2015 Aug; 5():12733. PubMed ID: 26235332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.
    Auvray M; Elaidi R; Ozguroglu M; Guven S; Gauthier H; Culine S; Caty A; Dujardin C; Auclin E; Thibaut C; Combe P; Tartour E; Oudard S
    Clin Genitourin Cancer; 2017 Jun; 15(3):e469-e476. PubMed ID: 27964892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder.
    Eggers H; Seidel C; Schrader AJ; Lehmann R; Wegener G; Kuczyk MA; Steffens S
    Med Oncol; 2013 Dec; 30(4):705. PubMed ID: 24005810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preoperative serum cystatin-C as an independent prognostic factor for survival in upper tract urothelial carcinoma.
    Tan P; Shi M; Chen J; Xu H; Xie N; Xu H; Jiang Y; Ai JZ; Liu LR; Yang L; Wei Q
    Asian J Androl; 2019; 21(2):163-169. PubMed ID: 30416134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.
    Cantiello F; Russo GI; Vartolomei MD; Farhan ARA; Terracciano D; Musi G; Lucarelli G; Di Stasi SM; Hurle R; Serretta V; Busetto GM; Scafuro C; Perdonà S; Borghesi M; Schiavina R; Cioffi A; De Berardinis E; Almeida GL; Bove P; Lima E; Ucciero G; Matei DV; Crisan N; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Mirone V; Shariat SF; Ferro M
    Eur Urol Oncol; 2018 Oct; 1(5):403-410. PubMed ID: 31158079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.
    Kijima T; Yamamoto H; Saito K; Kusuhara S; Yoshida S; Yokoyama M; Matsuoka Y; Numao N; Sakai Y; Matsubara N; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
    Cancer Immunol Immunother; 2021 Mar; 70(3):657-665. PubMed ID: 32876736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis.
    Mori K; Miura N; Mostafaei H; Quhal F; Motlagh RS; Lysenko I; Kimura S; Egawa S; Karakiewicz PI; Shariat SF
    Int J Clin Oncol; 2020 Aug; 25(8):1459-1474. PubMed ID: 32451768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.